- Home
- PNR vs RPRX Comparison
PNR vs RPRX Comparison
Compare PNR & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNR
- RPRX
- Stock Information
- Founded
- PNR 1966
- RPRX 1996
- Country
- PNR United Kingdom
- RPRX United States
- Employees
- PNR N/A
- RPRX N/A
- Industry
- PNR Industrial Machinery/Components
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- PNR Industrials
- RPRX Health Care
- Exchange
- PNR Nasdaq
- RPRX Nasdaq
- Market Cap
- PNR 17.4B
- RPRX 16.2B
- IPO Year
- PNR N/A
- RPRX 2020
- Fundamental
- Price
- PNR $107.04
- RPRX $38.51
- Analyst Decision
- PNR Buy
- RPRX Strong Buy
- Analyst Count
- PNR 14
- RPRX 3
- Target Price
- PNR $119.29
- RPRX $46.00
- AVG Volume (30 Days)
- PNR 1.3M
- RPRX 3.2M
- Earning Date
- PNR 10-21-2025
- RPRX 11-05-2025
- Dividend Yield
- PNR 0.93%
- RPRX 2.28%
- EPS Growth
- PNR N/A
- RPRX N/A
- EPS
- PNR 3.93
- RPRX 1.75
- Revenue
- PNR $4,128,399,999.00
- RPRX $2,349,844,000.00
- Revenue This Year
- PNR $2.97
- RPRX $36.16
- Revenue Next Year
- PNR $4.64
- RPRX $2.04
- P/E Ratio
- PNR $27.30
- RPRX $22.00
- Revenue Growth
- PNR 0.83
- RPRX 3.70
- 52 Week Low
- PNR $74.25
- RPRX $24.05
- 52 Week High
- PNR $113.95
- RPRX $41.24
- Technical
- Relative Strength Index (RSI)
- PNR 43.06
- RPRX 56.61
- Support Level
- PNR $104.65
- RPRX $36.03
- Resistance Level
- PNR $109.14
- RPRX $41.24
- Average True Range (ATR)
- PNR 2.79
- RPRX 1.17
- MACD
- PNR -0.22
- RPRX 0.28
- Stochastic Oscillator
- PNR 39.32
- RPRX 48.17
About PNR Pentair plc.
Pentair is a global leader in the water treatment industry, with 10,000 employees and a presence in 25 countries. Its business is organized into three segments: pool, water technologies, and flow. The company offers a wide range of water solutions, including energy-efficient swimming pool equipment, filtration solutions, and commercial and industrial pumps. Pentair generated approximately $4.1 billion in revenue in 2024.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.